A Phase 1, Randomized, Open-label, Single-center, Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults in a Nonendemic Region
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2018
At a glance
- Drugs TDENV LAV (Primary) ; TDENV PIV (Primary)
- Indications Dengue
- Focus Adverse reactions
- 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2018 Status changed from not yet recruiting to recruiting.
- 12 Oct 2017 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.